Gene therapy for high cholesterol in people with heart disease
Part of Brain & nervous system, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests an experimental medicine called VERVE-102 to lower cholesterol in people with or at high risk for heart disease. It may help reduce the risk of heart attacks and strokes by targeting a gene that affects cholesterol levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart or blood vessel disease (like a heart attack, stroke, or blocked arteries) or are at high risk for it.
- You do not have homozygous familial hypercholesterolemia (a rare genetic condition causing extremely high cholesterol).
- You do not have long-term liver disease.
- You are not currently taking a PCSK9 inhibitor (a type of cholesterol-lowering injection) and have not taken one recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new one-time treatment called VERVE-201 for people with very high cholesterol or triglycerides that don't get better with standard medicines. The goal is to see if it can safely lower these fats in your blood.
This study follows people who already received an experimental gene editing treatment for cardiovascular disease in a prior Verve trial. The goal is to monitor their health and any long-term effects over time.
This trial tests a new medicine called VERVE-102 for people with a specific type of high cholesterol (HeFH) or early coronary artery disease. It aims to see if it can help lower cholesterol levels.
This trial tests a one-time gene therapy to lower extremely high cholesterol in people with a rare inherited condition. It may help reduce heart attack risk in those who haven't responded to standard treatments.
This trial tests a new gene therapy called NGGT006 for people with a genetic form of high cholesterol that doesn't improve with standard treatments. It aims to lower cholesterol levels and reduce the risk of heart problems.
This trial tests a new gene therapy called YOLT-101 for people with familial hypercholesterolemia, a genetic condition that causes very high cholesterol. The treatment aims to lower cholesterol levels and reduce heart risks.
Hear when a new Atherosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.